IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
23.15
+0.97 (4.37%)
Jan 21, 2025, 4:00 PM EST - Market closed
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $3.92M in the twelve months ending September 30, 2024, down -83.30% year-over-year. In the year 2023, IDEAYA Biosciences had annual revenue of $23.39M, down -54.08%.
Revenue (ttm)
$3.92M
Revenue Growth
-83.30%
P/S Ratio
n/a
Revenue / Employee
$31,629
Employees
124
Market Cap
2.00B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
IDYA News
- 9 days ago - IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - PRNewsWire
- 23 days ago - IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PRNewsWire
- 25 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 weeks ago - IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - PRNewsWire
- 5 weeks ago - IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - PRNewsWire
- 5 weeks ago - IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PRNewsWire
- 6 weeks ago - IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PRNewsWire
- 6 weeks ago - IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - PRNewsWire